<p>西氏医药服务（NYSE:WST - 获取免费报告）在周三发布的研究报告中被 Zacks Research 的股票研究人员从 “持有” 评级上调至 “强力买入” 评级，Zacks.com 报道。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他分析师也对该股票发布了研究报告。Evercore 在 4 月 24 日的研究报告中重申了对西氏医药服务股票的 “跑赢大盘” 评级。瑞银集团在 2 月 13 日的研究报告中重申了 “买入” 评级，并设定了 340.00 美元的目标价。德意志银行在 2 月 13 日的研究报告中重申了 “买入” 评级，并设定了 315.00 美元的目标价。花旗集团在 4 月 24 日的研究报告中重申了对西氏医药服务的 “买入” 评级。最后，巴克莱在 4 月 27 日的研究报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该公司 “持平” 评级。两位研究分析师对该股票给予了强力买入评级，七位给予了买入评级，三位给予了持有评级。根据 MarketBeat.com 的数据，西氏医药服务目前的平均评级为 “适度买入”，共识目标价为 322.89 美元。</p>
<p><strong>阅读我们关于西氏医药服务的最新报告</strong></p>
<h2>西氏医药服务股票下跌 0.7%</h2>
<ul>
<li>什么因素将推动标准普尔 500 指数今年的表现？</li>
</ul>
<p>WST 股票在周三开盘价为 300.13 美元。该公司的市值为 212 亿美元，市盈率为 40.12，市盈增长比率为 2.53，贝塔值为 1.17。公司的债务与股本比率为 0.07，速动比率为 2.04，流动比率为 2.71。该公司的 50 日移动平均价格为 267.64 美元，200 日移动平均价格为 265.17 美元。西氏医药服务的年内最低价为 202.79 美元，年内最高价为 330.88 美元。</p>
<p>西氏医药服务（NYSE:WST - 获取免费报告）在 4 月 23 日星期四发布了季度财报。这家医疗器械供应商报告季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。该公司季度收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司季度收入同比增长 21.0%。在去年同期，该公司每股收益为 1.45 美元。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标设定为每股收益 2.050-2.120 美元。平均而言，股票研究分析师预计西氏医药服务今年将发布每股收益 8.61 美元。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务宣布其董事会于 2 月 17 日启动了一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
<h2>内部买卖</h2>
<p>在其他西氏医药服务的新闻中，首席会计官 Chad Winters 在 4 月 27 日星期一出售了 896 股公司的股票。股票以平均价格 300.67 美元出售，总价值为 269,400.32 美元。出售后，首席会计官持有 1,523 股公司的股票，价值为 457,920.41 美元。此次交易使其持股减少了 37.04%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，副总裁 Annette F. Favorite 在 4 月 27 日星期一出售了 2,817 股公司的股票。股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。出售完成后，副总裁直接持有公司 16,828 股，价值约为 5,135,905.60 美元。此次交易使其持股减少了 14.34%。该出售的 SEC 文件提供了更多信息。0.60% 的股票由内部人士持有。</p>
<h2>西氏医药服务的机构交易</h2>
<p>大型投资者最近调整了对该股票的持有。Elyxium Wealth LLC 在第四季度购买了西氏医药服务的新股份，价值 25,000 美元。Bayban 在第四季度购买了西氏医药服务的新股份，价值 27,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持股增加了 156.4%。Private Trust Co. NA 现在拥有 100 股这家医疗器械供应商的股票，价值 28,000 美元，此前在此期间又购买了 61 股。DV Equities LLC 在第四季度购买了西氏医药服务的新股份，价值 28,000 美元。最后，Cornerstone Planning Group LLC 在第一季度将其在西氏医药服务的持股增加了 90.9%。Cornerstone Planning Group LLC 现在拥有 105 股这家医疗器械供应商的股票，价值 26,000 美元，此前在此期间又购买了 50 股。对冲基金和其他机构投资者持有该公司 93.90% 的股票。</p>
<h2>西氏医药服务公司简介</h2>
<p>（获取免费报告）</p>
<p>西氏医药服务公司是一家全球开发和制造组件、系统和服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专业药物输送设备。西氏以其弹性密封件、密封和聚合物组件而闻名，这些产品能够保持无菌性并与敏感药物配方兼容。</p>
<p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过西氏医药服务</li>
<li>准备好：3 个即将到来的催化剂可能推动 Oracle 创下新高</li>
<li>应对大型制药专利悬崖的两种方式</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司在第一季度财报后的比较</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

美国医药设备 ETF - iShares

生物科技 ETF - VanEck Vectors

<p>Zacks Research 将西氏医药服务（NYSE:WST）的评级从 “持有” 上调至 “强力买入”。其他分析师，包括 Evercore 和 UBS，也重申了积极的评级，目标价格范围在 310 美元到 340 美元之间。该公司报告了强劲的季度收益，每股收益为 2.13 美元，营收为 8.449 亿美元，均超出预期。西氏医药还启动了一项 10 亿美元的股票回购计划，显示出对其股票价值的信心</p>

<p>West Pharmaceutical Services (NYSE:WST - Get Free Report) was upgraded by equities researchers at Zacks Research from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）在周三发布的研究报告中被 Zacks Research 的股票研究人员从 “持有” 评级上调至 “强力买入” 评级，Zacks.com 报道。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Other analysts have also issued research reports about the stock. Evercore reaffirmed an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. UBS Group reaffirmed a &#34;buy&#34; rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;buy&#34; rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Citigroup reaffirmed a &#34;buy&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, Barclays lifted their price target on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the company an &#34;equal weight&#34; rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $322.89.</p>
<div class="lb-trans"><p>其他分析师也对该股票发布了研究报告。Evercore 在 4 月 24 日的研究报告中重申了对西氏医药服务股票的 “跑赢大盘” 评级。瑞银集团在 2 月 13 日的研究报告中重申了 “买入” 评级，并设定了 340.00 美元的目标价。德意志银行在 2 月 13 日的研究报告中重申了 “买入” 评级，并设定了 315.00 美元的目标价。花旗集团在 4 月 24 日的研究报告中重申了对西氏医药服务的 “买入” 评级。最后，巴克莱在 4 月 27 日的研究报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该公司 “持平” 评级。两位研究分析师对该股票给予了强力买入评级，七位给予了买入评级，三位给予了持有评级。根据 MarketBeat.com 的数据，西氏医药服务目前的平均评级为 “适度买入”，共识目标价为 322.89 美元。</p>
</div><p><strong>Read Our Latest Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于西氏医药服务的最新报告</strong></p>
</div><h2>West Pharmaceutical Services Stock Down 0.7%</h2>
<div class="lb-trans"><h2>西氏医药服务股票下跌 0.7%</h2>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>什么因素将推动标准普尔 500 指数今年的表现？</li>
</ul>
</div><p>WST stock opened at $300.13 on Wednesday. The firm has a market cap of $21.20 billion, a PE ratio of 40.12, a PEG ratio of 2.53 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm's 50 day moving average price is $267.64 and its 200-day moving average price is $265.17. West Pharmaceutical Services has a one year low of $202.79 and a one year high of $330.88.</p>
<div class="lb-trans"><p>WST 股票在周三开盘价为 300.13 美元。该公司的市值为 212 亿美元，市盈率为 40.12，市盈增长比率为 2.53，贝塔值为 1.17。公司的债务与股本比率为 0.07，速动比率为 2.04，流动比率为 2.71。该公司的 50 日移动平均价格为 267.64 美元，200 日移动平均价格为 265.17 美元。西氏医药服务的年内最低价为 202.79 美元，年内最高价为 330.88 美元。</p>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services will post 8.61 EPS for the current year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）在 4 月 23 日星期四发布了季度财报。这家医疗器械供应商报告季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。该公司季度收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司季度收入同比增长 21.0%。在去年同期，该公司每股收益为 1.45 美元。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标设定为每股收益 2.050-2.120 美元。平均而言，股票研究分析师预计西氏医药服务今年将发布每股收益 8.61 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services announced that its Board of Directors has initiated a share repurchase plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.</p>
<div class="lb-trans"><p>西氏医药服务宣布其董事会于 2 月 17 日启动了一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the business's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company's stock, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他西氏医药服务的新闻中，首席会计官 Chad Winters 在 4 月 27 日星期一出售了 896 股公司的股票。股票以平均价格 300.67 美元出售，总价值为 269,400.32 美元。出售后，首席会计官持有 1,523 股公司的股票，价值为 457,920.41 美元。此次交易使其持股减少了 37.04%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，副总裁 Annette F. Favorite 在 4 月 27 日星期一出售了 2,817 股公司的股票。股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。出售完成后，副总裁直接持有公司 16,828 股，价值约为 5,135,905.60 美元。此次交易使其持股减少了 14.34%。该出售的 SEC 文件提供了更多信息。0.60% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>西氏医药服务的机构交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $25,000. Bayban purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 61 shares during the period. DV Equities LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $28,000. Finally, Cornerstone Planning Group LLC increased its position in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Elyxium Wealth LLC 在第四季度购买了西氏医药服务的新股份，价值 25,000 美元。Bayban 在第四季度购买了西氏医药服务的新股份，价值 27,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持股增加了 156.4%。Private Trust Co. NA 现在拥有 100 股这家医疗器械供应商的股票，价值 28,000 美元，此前在此期间又购买了 61 股。DV Equities LLC 在第四季度购买了西氏医药服务的新股份，价值 28,000 美元。最后，Cornerstone Planning Group LLC 在第一季度将其在西氏医药服务的持股增加了 90.9%。Cornerstone Planning Group LLC 现在拥有 105 股这家医疗器械供应商的股票，价值 26,000 美元，此前在此期间又购买了 50 股。对冲基金和其他机构投资者持有该公司 93.90% 的股票。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏医药服务公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏医药服务公司是一家全球开发和制造组件、系统和服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专业药物输送设备。西氏以其弹性密封件、密封和聚合物组件而闻名，这些产品能够保持无菌性并与敏感药物配方兼容。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs</li>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过西氏医药服务</li>
<li>准备好：3 个即将到来的催化剂可能推动 Oracle 创下新高</li>
<li>应对大型制药专利悬崖的两种方式</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司在第一季度财报后的比较</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

West Pharmaceutical Services (NYSE:WST) Upgraded to "Strong-Buy" at Zacks Research

Market Beat

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

标普健康医疗设备 ETF - SPDR

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

Evercore

瑞银集团

德意志银行

花旗

巴克莱银行

标普 500 指数

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

西氏医药服务（NYSE:WST）被 Zacks Research 升级为 “强力买入” 评级